



ATHORA NETHERLANDS 2022 RESULTS




ATHORA NETHERLANDS KEY FIGURES 2022




Premium income (€mln)




Direct Investment Income (€mln)




Total operating expenses (€mln)




Net underlying result (€mln)



Solvency II ratio



Total assets (€bn)



Financial Results

- Net Underlying Result of EUR 413 million (2021: EUR 302 million) primarily due to higher investment income, driven by the repositioning of the asset portfolio.
- Gross premiums of EUR 1,763 million increased by 2% compared to 2021 when excluding the impact of buy-out contracts thanks to growth in pension premiums.
- Increase of 7% in pension premiums evidences success against our strategy to grow in this market.
- Zwitterleven PPI continued to grow with deposits increasing by 23% to EUR 320 million.
- The Net Result IFRS for continuing operations of -/- EUR 928 million (2021: -/- EUR 27 million) was negatively impacted by the change in market value of investments from higher interest rates, spread widening and the strengthening of expense provisions.

Solvency II


- 2022 Solvency II ratio increased to 205% (YE21: 180%) for Athora Netherlands NV, driven by strong Operating Capital Generation (OCG), the positive impact of market movements in combination with management actions.
- 2022 Solvency II ratio of 207% (YE21: 180%) for SRLEV.

Strategic Progress

- Athora Netherlands' strategy to further grow as a leading pension insurer, offering sustainable pensions to our customers, was supported by three previously announced transactions.
 - An agreement with Willis Towers Watson (WTW) to acquire their EUR 1.1 billion Premium Pension Institution (PPI) in the Netherlands. Second
 - An agreement with Onderlinge 's-Gravenhage to acquire a EUR 0.3 billion 2nd pillar pension portfolio.
 - The transfer of the pension entitlements of Stichting Pensioenfonds A.C. Nielsen to Zwitterleven.
- In January 2023, the Executive Committee of Athora Netherlands was established with all functions represented, to support strategic delivery by enhancing the efficiency and effectiveness of our governance.

SOLVENCY POSITION INCREASED TO 205% DUE TO CAPITAL GENERATION AND POSITIVE MARKET IMPACTS, PARTLY OFFSET BY CONTINUED INVESTMENTS TO FURTHER IMPROVE FUTURE CAPITAL GENERATION

Solvency II development in 2022 (in %pt SII ratio)




Solvency II ratio increased from 180% to 205%


- In 2022, Athora has redefined the composition of **Operating Capital Generation (OCG)**. OCG contributed 20%-points to the Solvency II ratio in 2022. Continued repositioning of the asset portfolio, and a lower UFR drag due to the increase in interest rates contributed to a higher OCG especially in the second half of 2022 (15%-points)
- **Capital effects** reflect the impact of coupon payments on subordinated loans
- **Market impacts** were positive during 2022, driven by a strong increase of the VA from 3bps to 19bps, which was only partly offset by the negative impact of spread widening. The significant increase in interest rates had limited effect but the flattening of the yield at the long end of the curve had a positive impact on solvency. Other market movements which include inflation and the lower impact of equity shocks on SCR also had a positive impact on the Solvency II ratio
- **One-time items** relate primarily to the asset portfolio repositioning towards higher yielding investments to ensure higher future capital generation which decreased the ratio due to the associated higher SCR consumption.
- **Other** includes fiscal effects and the increase of the non-zero LACDT

BREAKDOWN OF ATHORA NL'S SOLVENCY II OWN FUNDS AND SCR FOR 2022

Eligible Own Funds (€bn)




SCR (€bn)



- **Eligible Own Funds** decreased compared to 2021 due to the increase and flattening of interest rates, higher investment management expenses, the decrease of the UFR level with 15 bps and the increase of tiering restrictions
- **Total SCR** lower in 2022
 - Despite the impact of the continued repositioning of the asset portfolio, the SCR market risk is lower due to the increase and flattening of interest rates and as a result of the lower asset base
 - Lower life-SCR due to the significant increase in interest rates and the organic development of required capital
 - Lower SCR due to the increase of the LACDT, mainly due to the increase of interest rates and higher spreads


SOLVENCY II RATIO SENSITIVITIES




- **Solvency II interest rate sensitivities** are stable as additional interest rate hedges were put in place to reduce interest rate sensitivity
- **Sensitivities are countercyclical** where the Solvency II ratio increases with higher spreads due to a lower exposure to private credits resulting in overcompensation of the Volatility Adjustment in the spread / VA sensitivities
- **Sensitivities of Equities and Real Estate** have increased following the repositioning towards return seeking investments

GOOD PROGRESS MADE IN POSITIONING TOWARDS NEW SAA

2021 (€38bn)



2022 (€29bn)



	2021	2022
Sovereigns + MMF	56.8%	46.5%
Sovereign AAA	22.4%	17.0%
Sovereign AA	6.1%	4.4%
Sovereign A / BBB	2.5%	0.1%
Other sovereigns	3.4%	3.9%
Supranationals	16.0%	6.0%
Money Market Funds	6.3%	15.0%
Collateralized loans	1.4%	1.4%
Mortgages	13.8%	15.6%

	2021	2022
Alternatives	3.1%	7.0%
Real estate	2.0%	3.8%
Equity	1.1%	3.2%
Credits	18.4%	18.0%
Euro financials	9.7%	9.1%
Euro corp	3.7%	4.2%
Asset backed securities	1.4%	0.4%
Covered bonds	0.2%	0.1%
Credits other	3.3%	4.3%
Private credits	6.4%	11.6%

Investment Strategy

- Total assets under management decreased significantly, mainly due to the impact of higher interest rates
- In line with our Strategic Asset Allocation (SAA) asset redeployment into Private Credits and Alternatives continued
- Consistent with the SAA, we expect to further increase our investment into Alternatives, Private Credits and Collateralized Loans which is intended to increase future investment income and capital generation

DISCLAIMER

This presentation has been prepared and issued by Athora Netherlands NV (“Athora Netherlands” or “the Company”). For the purposes of this notice, the presentation that follows (“the Presentation”) shall mean and include the slides that follow, the oral presentation of the slides by the Company, the question-and-answer session that follows that oral presentation, hard copies of this document and any materials distributed at, or in connection with, that presentation.

No reliance may or should be placed for any purposes whatsoever on the information contained in this Presentation or any other material discussed at the Presentation, or on its completeness, accuracy or fairness. The information and opinions contained in this Presentation and any other material discussed at the Presentation are provided as at the date of this Presentation and are subject to change without notice. No person is under any obligation to update, complete, revise or keep current the information contained in the Presentation.

This Presentation is released by Athora Netherlands NV and contains information that qualified or may have qualified as inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 (MAR).

This Presentation exclusively contains factual information and must not be interpreted as an opinion or recommendation with regard to the purchase or sale of securities issued by Athora Netherlands NV and/or one or more of its subsidiaries

This Presentation contains certain forward-looking statements that reflect the Company's intentions, beliefs, assumptions or current expectations about and targets for the Company's future result of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company operates, taking into account all information currently available to the Company, and are not necessarily indicative or guarantees of future performance and results. You should not place undue reliance on the forward-looking statements in this Presentation. The Company does not guarantee that the assumptions underlying the forward-looking statements in this presentation are free from errors, accept any responsibility for the future accuracy of the opinions expressed in this presentation or undertake any obligation to update the statements in this presentation to reflect subsequent events. No responsibility, obligation or liability (whether direct or indirect, in contract, tort or otherwise) is or will be accepted in relation to the Presentation by the Company or the Company's subsidiaries or associated companies, or any of their respective directors, officers, employees, advisers or agents. The information contained in the Presentation has not been independently verified. No representation or warranty, express or implied, is made as to the truth, fullness, accuracy, reasonableness or completeness of the information contained herein (or whether any information has been omitted from the Presentation) or any other information relating to the Company, the Company's subsidiaries or associated companies, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available by the Company or any of their respective directors, officers, employees, advisers or agents.